A recent study led by researchers at the University of Virginia School of Medicine found that patients with major depressive disorder (MDD) who had inadequate responses to standard antidepressants showed significant improvements in sexual function when treated with lumateperone. The study involved 480 participants who received either a 42 mg daily dose of lumateperone or a placebo in addition to their current antidepressant therapy.

Read More

The results indicated that the addition of lumateperone led to notable enhancements in sexual function across various groups, including individuals with pre-existing sexual dysfunction, women, and both younger and older adults. Improvements were observed in multiple aspects of sexual functioning, including desire, arousal, orgasm, and pleasure.

Approximately 68% of those with MDD experience sexual dysfunction, a common reason for discontinuing antidepressant treatment. Lead researcher Anita H. Clayton, MD, highlighted the significance of these findings in improving sexual health among patients facing depression.

MDD affects around 21 million adults in the United States, with sexual dysfunction linked to the condition itself and exacerbated by the side effects of common antidepressants, such as selective serotonin reuptake inhibitors (SSRIs). Clayton noted that patients receiving lumateperone as an adjunctive treatment reported both improvements in depressive symptoms, measured by the Montgomery-Asberg Depression Rating Scale (MADRS), and sexual functioning assessed through the Changes in Sexual Functioning Questionnaire (CSFQ-14) at the end of the 43-day treatment period. At the study's onset, 82.5% of participants had sexual dysfunction; by the conclusion, more than a quarter reported regular sexual function.

Women appeared to benefit more significantly than men, although improvements in sexual pleasure and arousal were noted for both sexes. Additionally, participants without initial sexual dysfunction did not experience any decline in sexual function while taking lumateperone.

Clayton emphasized the need for effective treatment strategies that do not exacerbate sexual dysfunction, especially for individuals who do not experience substantial relief from MDD symptoms with standard antidepressants. The results of this study have been published in The Journal of Clinical Psychiatry.